CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, today announced that investigators have been authorized under the study protocol to administer a third infusion of CER-1236 to a patient enrolled in the first cohort of its ongoing Phase 1 clinical trial. This additional infusion of 1 million CER-1236 cells per kilogram of body weight of the patient -- completed approximately one week ago and identical to the first two doses -- is intended to generate further safety and dosing information that may help assess the feasibility of a multi-dose administration strategy as an alternative to a single, higher-dose approach. The initial dose level for Cohort One was selected based on dose ranges commonly used in other adoptive T-cell therapy studies.  

Read more at globenewswire.com